Anti-PD-(L)1 induced hypophysitis differs from anti-CTLA-4 mono- or combination induced hypophysitis with regard to clinical symptoms, MRI abnormalities and the degree of hypopituitarism, which is more pronounced after anti-CTLA-4 mono- or combination therapy. Here, CTLA4 is linked to hypopituitarism.